Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England

The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications Vol. 15; no. 1; pp. 6085 - 12
Main Authors: Ip, Samantha, North, Teri-Louise, Torabi, Fatemeh, Li, Yangfan, Abbasizanjani, Hoda, Akbari, Ashley, Horne, Elsie, Denholm, Rachel, Keene, Spencer, Denaxas, Spiros, Banerjee, Amitava, Khunti, Kamlesh, Sudlow, Cathie, Whiteley, William N., Sterne, Jonathan A. C., Wood, Angela M., Walker, Venexia
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 31.07.2024
Nature Publishing Group
Nature Portfolio
Subjects:
2019-nCoV Vaccine mRNA-1273 - administration & dosage
2019-nCoV Vaccine mRNA-1273 - adverse effects
631/326/590
631/326/596/4130
692/699/75
692/700/1538
692/700/478/174
Adolescent
Adult
Adults
Aged
Aged, 80 and over
BNT162 Vaccine - administration & dosage
BNT162 Vaccine - adverse effects
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cerebral infarction
ChAdOx1 nCoV-19 - administration & dosage
ChAdOx1 nCoV-19 - adverse effects
Cohort Studies
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - adverse effects
Electronic health records
Electronic medical records
Embolism
England - epidemiology
Female
Heart diseases
Humanities and Social Sciences
Humans
Immunization
Immunization, Secondary - adverse effects
Incidence
Ischemia
Male
Middle Aged
mRNA
multidisciplinary
Myocardial infarction
Myocardial Infarction - epidemiology
Myocardial Infarction - etiology
Myocarditis
Myocarditis - epidemiology
Myocarditis - etiology
Pericarditis
Pulmonary Embolism - epidemiology
Pulmonary Embolism - etiology
Science
Science (multidisciplinary)
Thrombocytopenia
Thromboembolism
Thrombosis
Thrombosis - epidemiology
Thrombosis - etiology
Vaccination - adverse effects
Vaccines
Young Adult
England
United Kingdom > UK
ISSN:2041-1723, 2041-1723
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs. COVID-19 vaccines have been associated with rare cardiovascular and thrombotic complications. Here, the authors use population-based longitudinal electronic health record data from ~46 million adults in England to quantify these outcomes following different vaccine doses and schedules.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-024-49634-x